FDA approves first drug for postpartum depression

Author(s):

On March 19, the FDA approved Zulresso (brexanolone) injection for intravenous (IV) use for the treatment of postpartum depression. Zulresso will be available only through a restricted program that requires the drug be administered by a healthcare provider in a certified health care facility.

Read more at FDA.gov.

LEAVE A REPLY

Please enter your comment!
Please enter your name here